Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arctic Bioscience AS ( (DE:9TD) ) just unveiled an announcement.
Arctic Bioscience has announced that a group of investors has converted NOK 3 million of outstanding debt into shares as part of a NOK 15 million convertible loan. This conversion will lead to a capital increase, resulting in the issuance of 26,689,343 shares, reflecting investor confidence in the company’s strategic direction and potential market growth.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company specializing in the development and commercialization of pharmaceutical products and dietary supplements derived from unique bioactive marine raw materials. The company is advancing HRO350, an oral drug candidate aimed at treating mild to moderate psoriasis, and markets dietary supplements globally under the brand ROMEGA®.
YTD Price Performance: 104.62%
Average Trading Volume: 1,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €7.55M
For an in-depth examination of 9TD stock, go to TipRanks’ Stock Analysis page.